Literature DB >> 10028915

Occurrence of the diffuse amyloid beta-protein (Abeta) deposits with numerous Abeta-containing glial cells in the cerebral cortex of patients with Alzheimer's disease.

H Akiyama1, H Mori, T Saido, H Kondo, K Ikeda, P L McGeer.   

Abstract

Diffuse amyloid beta-protein (Abeta) deposits with numerous glial cells containing C-terminal Abeta fragments occur in the cerebral cortex of patients with Alzheimer's disease. By using a panel of antibodies specific for various epitopes in the Abeta peptide, we have investigated the immunohistochemical nature of the diffuse Abeta deposits. The extracellular material contains Abeta with a C-terminus at residue valine40 (Abeta40) as well as residues alanine42/threonine43 (Abeta42). The N-termini include aspartate1, pyroglutamate3, and pyroglutamate11, with pyroglutamate3 being dominant. Microglia and astrocytes in and around these deposits contain intensely staining granules. Most of these granules are negative for antibodies to the N-terminally located sequences of Abeta. These include 6E10 (Abeta1-17), 6F/3D (Abeta8-17), and the N-terminal antibodies specific to aspartate1, pyroglutamate3, and pyroglutamate11. The C-termini of intraglial Abeta are comparable with those of the extracellular deposits. The microglia and astrocytes have quiescent morphology compared with those associated with senile plaques and other lesions such as ischemia. Complement activation in these deposits is not prominent and often below the sensitivity of immunohistochemical detection. Although factors which may cause this type of deposit remain unclear, lack of strong tissue responses suggests that these deposits are a very early stage of Abeta deposition. They were found only inconsistently and were absent in a number of cases examined in this study. Further analysis of these deposits might provide important clues regarding the accumulation and clearance of Abeta in Alzheimer's disease brain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10028915     DOI: 10.1002/(sici)1098-1136(19990215)25:4<324::aid-glia2>3.0.co;2-5

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  35 in total

1.  Amyloid-β oligomers stimulate microglia through a tyrosine kinase dependent mechanism.

Authors:  Gunjan Dhawan; Angela M Floden; Colin K Combs
Journal:  Neurobiol Aging       Date:  2011-12-01       Impact factor: 4.673

2.  Astrocytes Surviving Severe Stress Can Still Protect Neighboring Neurons from Proteotoxic Injury.

Authors:  Amanda M Gleixner; Jessica M Posimo; Deepti B Pant; Matthew P Henderson; Rehana K Leak
Journal:  Mol Neurobiol       Date:  2015-09-15       Impact factor: 5.590

Review 3.  Inflammation and microglia actions in Alzheimer's disease.

Authors:  Colin K Combs
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-11       Impact factor: 4.147

Review 4.  Microglia and inflammation in Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 5.  Nuclear receptors as therapeutic targets for Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  Expert Opin Ther Targets       Date:  2011-07-01       Impact factor: 6.902

6.  Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β.

Authors:  Mark L Cohen; Chae Kim; Tracy Haldiman; Mohamed ElHag; Prachi Mehndiratta; Termsarasab Pichet; Frances Lissemore; Michelle Shea; Yvonne Cohen; Wei Chen; Janis Blevins; Brian S Appleby; Krystyna Surewicz; Witold K Surewicz; Martha Sajatovic; Curtis Tatsuoka; Shulin Zhang; Ping Mayo; Mariusz Butkiewicz; Jonathan L Haines; Alan J Lerner; Jiri G Safar
Journal:  Brain       Date:  2015-02-15       Impact factor: 13.501

Review 7.  The evolving biology of microglia in Alzheimer's disease.

Authors:  Tarja M Malm; Taylor R Jay; Gary E Landreth
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

8.  Microvessel occlusions alter amyloid-beta plaque morphology in a mouse model of Alzheimer's disease.

Authors:  Yuying Zhang; Evan D Bander; Yurim Lee; Celia Muoser; Chris B Schaffer; Nozomi Nishimura
Journal:  J Cereb Blood Flow Metab       Date:  2019-11-19       Impact factor: 6.200

9.  Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice.

Authors:  Bingqian Liu; Suhail Rasool; Zhikuan Yang; Charles G Glabe; Steven S Schreiber; Jian Ge; Zhiqun Tan
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

10.  IRF-8 is Involved in Amyloid-β1-40 (Aβ1-40)-induced Microglial Activation: a New Implication in Alzheimer's Disease.

Authors:  Qinggan Zeng; Rongyong Man; Yifeng Luo; Ling Zeng; Yushi Zhong; Bingxun Lu; Xiaofeng Wang
Journal:  J Mol Neurosci       Date:  2017-08-31       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.